Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations

By afschroeder • February 27, 2026

Napolitano A, Joensuu H, Rothschild S, Evans D, Heinrich MC, Sutton TL, Mayo SC, Boye K, Falkenhorst J, Le Cesne A, Hohenberger P, Rutkowski P, van Houdt WJ, Steeghs N, Gelderblom H, Desar IME, Pantaleo MA, Nishida T, Reichardt P, Blay JY, Somaiah N, Haddad EFN, Grignani G, Baldi GG, Steigen SE, Braconi C, Nilsson B, Singh AS, Fumagalli E, Cananzi FCM, Italiano A, Ceruso MS, Brunello A, Magnússon MK, Jonasson JG, Marquina G, Hindi N, Cirilli C, Federico M, Fausti V, Bordoni A, Sufliarsky J, Mazzocca A, Martin-Broto J, Gronchi A, Trent JC, Casali PG, Bauer S, Jones RL, Vincenzi B. Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations. JAMA Oncol. 2026 Feb 26. doi: 10.1001/jamaoncol.2026.0007. Epub ahead of print. PMID: 41746633.

Tags: Hematology/Oncology, Publications

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis

Britten K, Lipsyc-Sharf M, Yang EH, McCloskey S, Sedrak MS, Teshome M, LaBarbera J, Bardia A, McAndrew N. Socioeconomic disparities in long-term heart failure risk[...]

Cardiotoxicity of T cell immunotherapies

Raddatz MA, Stein-Merlob AF, Mahmood SS, Ganatra S, Addison D, Lin TL, Larson SM, Yang EH. Cardiotoxicity of T cell immunotherapies. Nat Rev Cardiol. 2026[...]

Evaluating the feasibility and efficacy of exercise interventions for older survivors of cancer

Ji J, Niknafs A, Jones LW. Evaluating the feasibility and efficacy of exercise interventions for older survivors of cancer. Cancer. 2026 Mar 1;132(5):e70278. doi: 10.1002/cncr.70278.[...]